NICE Rejects Pierre Fabre's Braftovi for Colorectal Cancer

The UK’s National Institutes of Health and Care Excellence (NICE) has recommended against the use of Pierre Fabre's Braftovi (encorafenib) with cetuximab by the National Health Service (NHS) for treating adults with BRAF V600E mutation-positive colorectal cancer that has spread in the body and who have had a previous systemic treatment.

NICE found that the combination treatment offered a benefit compared to Folfiri with cetuximab or irinotecan plus cetuximab but said the combination’s cost relative to its effectiveness exceeded what it considers acceptable for the NHS.  

Braftovi is also used in combination with binimetinib to treat melanoma that cannot be removed by surgery or has spread.